Shares in Medivir AB dropped by 21.25 percent Tuesday on news that partner Boehringer Ingelheim GmbH opted to discontinue development of the HIV drug MIV-310 (alovudine) following a Phase IIa trial in which the compound failed to attain a target efficacy level. (BioWorld International)